MPO

Summary

MPO (myeloperoxidase, HGNC:7218) is a protein-coding gene on chromosome 17q22, encoding Myeloperoxidase (P05164). Peroxidase that plays a central role in the host defense system of polymorphonuclear leukocytes by mediating both (1) formation of neutrophil extracellular trap (NETs) and (2) microbicidal activity.

Myeloperoxidase (MPO) is a heme protein synthesized during myeloid differentiation that constitutes the major component of neutrophil azurophilic granules. Produced as a single chain precursor, myeloperoxidase is subsequently cleaved into a light and heavy chain. The mature myeloperoxidase is a tetramer composed of 2 light chains and 2 heavy chains. This enzyme produces hypohalous acids central to the microbicidal activity of neutrophils.

Source: NCBI Gene 4353 — RefSeq curated summary.

At a glance

• Gene–disease (curated): myeloperoxidase deficiency (Moderate, GenCC)
• GWAS associations: 32 (top 4% of genes corpus-wide)
• Clinical variants (ClinVar): 101 total — 1 pathogenic, 5 likely-pathogenic
• GTEx eGene: eQTL in 9 tissues, sQTL in 0 (q < 0.05)
• Phenotypes (HPO): 14
• Drug target: yes — 1 curated mechanism-of-action drug; 19 molecules with ChEMBL bioactivity (top 2% of genes corpus-wide)
• Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 0.99 (unconstrained)
• MANE Select transcript: NM_000250
• Interaction hub: 3,026 STRING partners (top 2% of genes corpus-wide)
• Notable: 101 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7218
Approved symbol	MPO
Name	myeloperoxidase
Location	17q22
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000005381
Ensembl biotype	protein_coding
OMIM	606989
Entrez	4353

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 2 protein_coding, 2 protein_coding_CDS_not_defined, 2 retained_intron, 1 nonsense_mediated_decay

MANE Select: ENST00000225275

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 1, TSL 2: 1, TSL 3: 3

ENST00000225275, ENST00000577220, ENST00000578493, ENST00000580005, ENST00000581022, ENST00000699291, ENST00000699292

RefSeq mRNA: 1 — MANE Select: NM_000250 NM_000250

CCDS: CCDS11604

Canonical transcript exons

ENST00000225275 — 12 exons

Exon	Start	End
ENSE00000480273	58279008	58279214
ENSE00000480274	58277827	58278145
ENSE00000480276	58273414	58273669
ENSE00000739347	58271655	58271892
ENSE00000739352	58275542	58275702
ENSE00000739356	58279297	58279426
ENSE00000739375	58279523	58279646
ENSE00000739378	58279839	58280014
ENSE00000739393	58280366	58280459
ENSE00001151664	58269855	58270863
ENSE00001151667	58280605	58280935
ENSE00002445423	58272748	58272918

Expression profiles

Bgee: expression breadth ubiquitous, 157 present calls, max score 99.55.

FANTOM5 (CAGE): breadth broad, TPM avg 34.8139 / max 8476.8700, expressed in 296 samples.

Highest expression (Bgee): trabecular bone tissue, bone marrow cell, bone marrow, bone element, monocyte.

Genetic regulation across tissues (GTEx eQTL / sQTL)

MPO is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 9 tissues and its splicing (sQTL) in 0 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

9 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Whole Blood	eqtl	4.9e-04	-0.23	17:58336274:C:A
Artery Coronary	eqtl	1.6e-02	-0.52	17:57686805:TAGAG:T
Artery Tibial	eqtl	1.9e-02	+0.67	17:57530790:G:A
Brain Cerebellar Hemisphere	eqtl	2.0e-02	+0.30	17:58289333:C:G
Brain Cerebellum	eqtl	2.1e-02	+0.29	17:58306661:A:C
Brain Hypothalamus	eqtl	2.1e-02	+3.45	17:57737692:T:A
Brain Cortex	eqtl	2.2e-02	-1.22	17:57319957:C:T
Esophagus Mucosa	eqtl	2.5e-02	+1.12	17:57757728:G:A
Artery Aorta	eqtl	4.6e-02	-0.28	17:57728074:C:T

FANTOM5 promoters

showing 10 of 33 alternative TSS:

Promoter ID	TPM avg	Samples expressed
167226	22.8882	67
167225	6.1396	46
167224	2.3700	32
167206	0.3604	20
167198	0.3227	154
167197	0.2957	127
167223	0.2001	19
167216	0.1870	16
167202	0.1811	15
167192	0.1752	20

Top tissues by expression

showing 100 of 286 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
trabecular bone tissue	UBERON:0002483	99.55	gold quality
bone marrow cell	CL:0002092	99.24	gold quality
bone marrow	UBERON:0002371	98.81	gold quality
bone element	UBERON:0001474	96.61	gold quality
monocyte	CL:0000576	88.14	gold quality
mononuclear cell	CL:0000842	88.03	gold quality
leukocyte	CL:0000738	86.92	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	83.55	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	80.89	gold quality
granulocyte	CL:0000094	80.30	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	77.52	silver quality
spleen	UBERON:0002106	75.99	gold quality
amniotic fluid	UBERON:0000173	74.88	gold quality
blood	UBERON:0000178	74.55	gold quality
right lung	UBERON:0002167	71.54	gold quality
minor salivary gland	UBERON:0001830	69.88	gold quality
saliva-secreting gland	UBERON:0001044	69.57	gold quality
endometrium epithelium	UBERON:0004811	68.42	gold quality
thymus	UBERON:0002370	66.05	silver quality
mouth mucosa	UBERON:0003729	66.01	gold quality
upper lobe of left lung	UBERON:0008952	65.73	gold quality
prefrontal cortex	UBERON:0000451	64.41	gold quality
upper lobe of lung	UBERON:0008948	64.11	gold quality
Brodmann (1909) area 10	UBERON:0013541	63.76	gold quality
gastrocnemius	UBERON:0001388	62.39	gold quality
pancreatic ductal cell	CL:0002079	61.74	silver quality
muscle of leg	UBERON:0001383	61.69	gold quality
nasal cavity mucosa	UBERON:0001826	61.38	gold quality
vena cava	UBERON:0004087	61.33	gold quality
adenohypophysis	UBERON:0002196	60.50	gold quality
tibia	UBERON:0000979	60.43	silver quality
right lobe of liver	UBERON:0001114	60.40	gold quality
right frontal lobe	UBERON:0002810	60.40	gold quality
cingulate cortex	UBERON:0003027	60.34	gold quality
anterior cingulate cortex	UBERON:0009835	60.06	gold quality
pituitary gland	UBERON:0000007	59.16	gold quality
hindlimb stylopod muscle	UBERON:0004252	59.15	gold quality
frontal cortex	UBERON:0001870	59.01	gold quality
muscle organ	UBERON:0001630	58.99	gold quality
tonsil	UBERON:0002372	58.61	gold quality
neocortex	UBERON:0001950	58.57	gold quality
tendon of biceps brachii	UBERON:0008188	57.86	gold quality
lung	UBERON:0002048	57.39	gold quality
Brodmann (1909) area 9	UBERON:0013540	57.18	gold quality
tibialis anterior	UBERON:0001385	57.16	silver quality
dorsolateral prefrontal cortex	UBERON:0009834	57.03	gold quality
putamen	UBERON:0001874	56.73	gold quality
vermiform appendix	UBERON:0001154	56.15	gold quality
parotid gland	UBERON:0001831	56.14	gold quality
myocardium	UBERON:0002349	56.07	gold quality
cerebral cortex	UBERON:0000956	55.99	gold quality
descending thoracic aorta	UBERON:0002345	55.78	gold quality
lymph node	UBERON:0000029	55.52	gold quality
primary visual cortex	UBERON:0002436	55.46	gold quality
hypothalamus	UBERON:0001898	55.29	gold quality
caudate nucleus	UBERON:0001873	55.24	gold quality
forebrain	UBERON:0001890	55.22	gold quality
amygdala	UBERON:0001876	55.21	gold quality
liver	UBERON:0002107	55.08	gold quality
telencephalon	UBERON:0001893	54.98	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	54.97	gold quality
ileal mucosa	UBERON:0000331	54.93	silver quality
endothelial cell	CL:0000115	54.91	gold quality
inferior olivary complex	UBERON:0002127	54.89	gold quality
caecum	UBERON:0001153	54.58	gold quality
brain	UBERON:0000955	54.54	gold quality
central nervous system	UBERON:0001017	54.42	gold quality
nucleus accumbens	UBERON:0001882	54.19	gold quality
substantia nigra	UBERON:0002038	54.17	gold quality
right hemisphere of cerebellum	UBERON:0014890	54.07	gold quality
cranial nerve II	UBERON:0000941	53.76	gold quality
right atrium auricular region	UBERON:0006631	53.60	gold quality
quadriceps femoris	UBERON:0001377	53.46	gold quality
deltoid	UBERON:0001476	53.34	gold quality
cardiac atrium	UBERON:0002081	53.29	gold quality
cerebellar cortex	UBERON:0002129	53.27	gold quality
cerebellar hemisphere	UBERON:0002245	53.20	gold quality
midbrain	UBERON:0001891	52.80	gold quality
cerebellum	UBERON:0002037	52.79	gold quality
epithelium of esophagus	UBERON:0001976	52.74	gold quality
nasal cavity epithelium	UBERON:0005384	52.72	gold quality
heart left ventricle	UBERON:0002084	52.56	gold quality
vastus lateralis	UBERON:0001379	52.41	gold quality
esophagus squamous epithelium	UBERON:0006920	52.39	gold quality
heart	UBERON:0000948	52.36	gold quality
cardiac ventricle	UBERON:0002082	52.34	gold quality
thoracic aorta	UBERON:0001515	52.08	gold quality
muscle tissue	UBERON:0002385	51.81	gold quality
Ammon’s horn	UBERON:0001954	51.77	gold quality
occipital lobe	UBERON:0002021	51.75	gold quality
ascending aorta	UBERON:0001496	51.67	gold quality
skeletal muscle tissue	UBERON:0001134	51.60	gold quality
epithelial cell of pancreas	CL:0000083	51.50	gold quality
apex of heart	UBERON:0002098	51.41	gold quality
temporal lobe	UBERON:0001871	51.26	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	51.25	gold quality
Brodmann (1909) area 46	UBERON:0006483	51.14	gold quality
right coronary artery	UBERON:0001625	51.10	gold quality
smooth muscle tissue	UBERON:0001135	51.07	gold quality
spinal cord	UBERON:0002240	50.67	gold quality

Single-cell (SCXA)

Detected in 15 experiment(s), a significant marker in 15.

Experiment	Marker?	Max mean expression
E-MTAB-9801	yes	28866.69
E-MTAB-9067	yes	23589.16
E-GEOD-89232	yes	18532.04
E-GEOD-100618	yes	10251.11
E-CURD-112	yes	9740.02
E-CURD-6	yes	9221.90
E-CURD-122	yes	8671.28
E-MTAB-10432	yes	7989.05
E-HCAD-6	yes	6014.37
E-MTAB-7407	yes	4799.12
E-MTAB-10042	yes	4335.14
E-HCAD-4	yes	4312.68
E-MTAB-8884	yes	3351.29
E-GEOD-76312	yes	3050.07
E-ANND-3	no	0.00

HPA expression

RNA tissue specificity: Tissue enriched

34 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Bone marrow	tissue	3249.5	high
Salivary gland	tissue	9.9	not detected
Thymus	tissue	6.9
Skin 1	tissue	3.7	not detected
Pituitary gland	tissue	1.5
Spleen	tissue	1.5	not detected
Lymph node	tissue	1.2	not detected
Placenta	tissue	0.9	not detected
Liver	tissue	0.7	not detected
Amygdala	tissue	0.4
Locus coeruleus	tissue	0.4
Postcentral gyrus	tissue	0.4
Hippocampal formation	tissue	0.3
Urinary bladder	tissue	0.2	not detected
Epididymis	tissue	0.2	not detected
Nucleus accumbens	tissue	0.2
Hippocampus	tissue	0.2	not detected
Adrenal gland	tissue	0.2	not detected
Appendix	tissue	0.2	not detected
Testis	tissue	0.1	not detected
Cerebral cortex	tissue	0.1	not detected
Retina	tissue	0.1
Vagina	tissue	0.1	not detected
Rectum	tissue	0.1	not detected
Smooth muscle	tissue	0.1	not detected
Tongue	tissue	0.1
Hypothalamus	tissue	0.1
Thyroid gland	tissue	0.1	not detected
Lung	tissue	0.1	not detected
Small intestine	tissue	0.1	not detected
Tonsil	tissue	0.1	not detected
Periaqueductal gray	tissue	0.1
Fallopian tube	tissue	0.1	not detected
Temporal cortex	tissue	0.1

Brain sub-regions (HPA Brain Atlas): detected in 183; highest nTPM — Area parastriata, superior (0.4), Dorsal raphe nucleus (0.4), Inferior parietal lobule (0.4), Mammillary body (0.4), Medial vestibular nucleus (0.4).

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CEBPA, CEBPE, CEBPG, FOXC1, HBP1, MYC, MYCN, NR1H3, PITX3, PPARA, PPARG, RARA, RUNX1, RUNX2, RXRA, SP1, SPI1, TAL1, TFDP1, TP53, WT1, ZNF296

miRNA regulators (miRDB)

Targeting MPO by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

showing 30 of 34 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-3173-3P	99.98	66.49	1217
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-4694-3P	99.79	69.53	2640
HSA-MIR-1273H-5P	99.77	66.32	2471
HSA-MIR-30B-3P	99.70	65.76	2325
HSA-MIR-3689A-3P	99.70	65.73	2306
HSA-MIR-3689B-3P	99.70	65.71	2311
HSA-MIR-3689C	99.70	65.71	2311
HSA-MIR-6779-5P	99.70	65.76	2363
HSA-MIR-4666B	99.64	68.69	1282
HSA-MIR-4276	99.56	67.66	2514
HSA-MIR-451B	99.55	68.28	1380
HSA-MIR-5683	99.36	68.59	2083
HSA-MIR-183-5P	99.31	72.27	1164
HSA-MIR-7158-5P	99.25	67.95	796
HSA-MIR-877-3P	99.09	68.10	1637
HSA-MIR-224-3P	98.91	68.42	1815
HSA-MIR-522-3P	98.91	68.56	1817
HSA-MIR-887-5P	98.82	65.90	1347
HSA-MIR-4297	98.77	66.95	2013
HSA-MIR-4710	98.61	65.96	1048
HSA-MIR-6827-5P	98.46	64.88	1256
HSA-MIR-6847-5P	97.93	66.74	1808
HSA-MIR-5581-5P	97.91	66.50	965
HSA-MIR-30C-1-3P	97.80	66.36	1499

Functional genomics

gnomAD constraint: pLI 3.39e-16, LOEUF 0.992, missense Z 0.82 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000225275 — one region, missense o/e 0.96.

Literature-anchored findings (GeneRIF, showing 40)

• Binding studies of myeloperoxidase support a model for a single common binding site for halides and thiocyanate as substrates or as inhibitors near the delta-meso carbon of the porphyrin ring in the enzyme. (PMID:11705390)
• The photoprotein pholasin as a luminescence substrate for detection of superoxide anion radicals and myeloperoxidase activity in stimulated neutrophils (PMID:11811524)
• Increased myeloperoxidase and lipid peroxide-modified protein in gynecological malignancies (LOOH-RSA, lipid peroxide-modified protein) (PMID:11813987)
• Neutrophils use MPO to initiate lipid peroxidation in whole plasma through multiple distinct diffusible substrates. Multiple endogenous diffusible substrates for myeloperoxidase in plasma are identified. (PMID:11861298)
• investigation of molecular mechanism of MPO-mediated apoptosis and caspase-3 activation (PMID:11981455)
• up-regulated by the AML1-MTG8 fusion protein, suggesting a role in the granulocytic maturation characteristic of the t(8;21) acute myelogenous leukemia (PMID:11986950)
• A common functional MPO promoter polymorphism (-463 G/A) is associated with increased incidence and clinical aspects of ANCA-associated small vessel vasculitis (PMID:12027420)
• MPO was observed to modulate the vascular signaling and vasodilatory functions of nitric oxide (NO) during acute inflammation (PMID:12089442)
• We confirm that the MPO -463 A variant affords a protective effect against lung cancer risk in smokers, which was strongest for SCLC patients. (PMID:12432558)
• Relative to subjects with the MPO G/G genotype, a significant decreased risk of lung cancer was found for carriers of G/A genotype. (PMID:12496042)
• Myeloperoxidase gene polymorphism does not decrease lung neoplasm susceptibility in caucasians. These findings are in contrast with the earlier studies suggesting a protective effect of carrying the variant A allele. (PMID:12496043)
• Lung cancer risk associated with genetic polymorphism in myeloperoxidase (-463 G/A) in a Chinese population (PMID:12515618)
• These data reveal substantial differences between the two known heme peroxidase superfamilies and reflect the dramatic differences observed in the oxidisability of substrates by the myeloperoxidase redox intermediates compound I and compound II. (PMID:12565898)
• Mediates lipid peroxidation of low-density lipoproteins as modulated by flavonoids. (PMID:12606047)
• Using mass spectrometric method, two products of myeloperoxidase, 5-chlorouracil and 5-bromouracil, were detected in neutrophil-rich human inflammatory tissue; in vitro mechanistic studies were also performed. (PMID:12707270)
• Expression of myeloperoxidase by neutrophils is necessary for their activation by anti-neutrophil cytoplasm autoantibodies against myeloperoxidase. (PMID:12773517)
• Lacrimal fluid peroxidase activity differs in men and women: the gender-related difference accentuates during ageing, probably owing to changing estrogen levels. (PMID:12792137)
• Myeloperoxidase promotor polymorphism is associated with hepatoblastoma (PMID:12800195)
• MPO polymorphism were associated with the extent of brain damage and the functional outcome rather than with the risk of developing brain infarction. (PMID:12818404)
• Myeloperoxidase (MPO) gene variation may modify the extent of advanced atherosclerotic lesions in the human aorta in early middle age. (PMID:12861032)
• In subjects with the high expression genotype of myeloperoxidase, the progression of atherosclerosis was significantly faster in the control group than in the hormone replacement therapy group, whereas in A allele carriers there were no differences (PMID:12915675)
• chemical mechanism behind the bactericidal action of the MPO-H(2)O(2)-Cl(-) system (PMID:12950060)
• in patients with acute coronary syndromes, MPO serum levels powerfully predict an increased risk for subsequent cardiovascular events; MPO may serve as both a marker and mediator of vascular inflammation (PMID:12952835)
• study shows that peroxisome proliferator-activated receptor gamma (PPARgamma) agonists strongly regulate myeloperoxidase gene expression through the Alu element repeats (PMID:14668325)
• These findings provide evidence that myeloperoxidase polymorphism is associated with coronary artery reactivity. (PMID:14730210)
• The heme-containing protein myeloperoxidase is released from stimulated polymorphonuclear leukocytes at sites of inflammation (PMID:14972011)
• Myeloperoxidase polymorphism related to cardiovascular events in coronary artery disease (PMID:15006595)
• The presence of MPO-G/G and A2M-Val/Val genotypes synergistically increased the risk of AD (OR, 25.5; 95% CI, 4.65-139.75). (PMID:15023809)
• Analysis of polymorphism in chronic renal failure patients undergoing hemodialysis. (PMID:15068388)
• the MPO/H2O2/SCN- system may have the potential to play a significant role in the oxidative modification of LDL (PMID:15203186)
• MPO G/G genotype may be one of the genetic factors influencing the progression rate of disability in multiple sclerosis patients. (PMID:15222689)
• Myeloperoxidase was detected in neurons. The increase in neuronal myeloperoxidase expression we observed in Alzheimer disease brains raises the possibility that the enzyme contributes to the oxidative stress implicated in the pathogenesis of the disorder (PMID:15255951)
• MPO appears to be an important modulator of vasomotor function in inflammatory vascular disease (PMID:15304260)
• Insights into mechanisms for inactivating MPO and the novel mode of oxygen binding to the hemoprotein may provide important clues toward understanding the catalytic action of MPO. (PMID:15350145)
• involvement of MPO in the antituberculous, immunological response implies its connection with TNF-alpha and IL-12 activation. (PMID:15379210)
• May represent an important pathway in diabetes complications and a new mechanism in phagocyte- and systemic infection-induced exacerbation of diabetic vascular diseases. (PMID:15504976)
• Mutations of the gene associated with MPO deficiency in Italian patients. (PMID:15507752)
• Mutations of the gene associated with MPO deficiency in Japanese patients. (PMID:15507753)
• Post-translational processing of pro-MPO, MPO secretion and storage, and the role of MPO in signal transduction in granulocytes. (PMID:15507754)
• Myeloperoxidase (MPO)-specific antibodies against neutrophils, anti-neutrophil cytoplasmic antibodies (MPO-ANCA) is involved in the development of vasculitis. (PMID:15507759)

Cross-species orthologs

11 orthologs

Organism	Symbol	Gene ID
danio_rerio	epx	ENSDARG00000012535
mus_musculus	Mpo	ENSMUSG00000009350
rattus_norvegicus	Mpo	ENSRNOG00000008310
drosophila_melanogaster	Pxd	FBGN0004577
drosophila_melanogaster	Pxn	FBGN0011828
drosophila_melanogaster	CG4009	FBGN0038469
drosophila_melanogaster	cysu	FBGN0038511
caenorhabditis_elegans		WBGENE00004256
caenorhabditis_elegans		WBGENE00004257
caenorhabditis_elegans		WBGENE00016700
caenorhabditis_elegans		WBGENE00019613

Paralogs (5): TPO (ENSG00000115705), EPX (ENSG00000121053), PXDN (ENSG00000130508), PXDNL (ENSG00000147485), LPO (ENSG00000167419)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:97137) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 12 distinct phenotype terms.

Mouse phenotype (MP)	Records
abnormal neutrophil physiology	3
atherosclerotic lesions	2
increased susceptibility to fungal infection	2
increased susceptibility to induced morbidity/mortality	2
increased monocyte cell number	1
decreased inflammatory response	1
abnormal muscle fiber morphology	1
increased susceptibility to experimental autoimmune encephalomyelitis	1
sepsis	1
abnormal response to injury	1
abnormal metabolism	1
increased physiological sensitivity to xenobiotic	1

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Bubalus bubalis	A5JUY8	99.4%	Diamond
Bos taurus	P80025	99.4%	Diamond
Capra hircus	A0A452E9Y6	95.1%	Diamond
Oryctolagus cuniculus	O02768	90.9%	Diamond
Equus caballus	O19183	90.9%	Diamond
Cavia porcellus	P70682	90.2%	Diamond
Caenorhabditis briggsae	A8WQH2	87.3%	Diamond
Mesocricetus auratus	Q8R481	84.6%	Diamond
Gallus gallus	P27607	82.1%	Diamond
Xenopus tropicalis	A4IGL7	81.7%	Diamond
Canis lupus familiaris	Q8HYB7	74.2%	Diamond
Sus scrofa	P09933	73.3%	Diamond
Anopheles gambiae	Q7QH73	51.4%	Diamond
Aedes aegypti	P82600	49.3%	Diamond
Lottia gigantea	B3A0P3	45.9%	Diamond
Pinctada margaritifera	H2A0M7	36.6%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
MIR4736	ncRNA	100616220
MIR142HG	ncRNA	123466215
HSF5	protein-coding	124535
LPO	protein-coding	4025
MIR142	ncRNA	406934
RNF43	protein-coding	54894
SUPT4H1	protein-coding	6827
MTMR4	protein-coding	9110
TSPOAP1	protein-coding	9256
MKS1	protein-coding	54903
EPX	protein-coding	8288
TSPOAP1-AS1	ncRNA	100506779
OR4D2	protein-coding	124538

Protein

Protein identifiers

Myeloperoxidase — P05164 (reviewed: P05164)

All UniProt accessions (3): P05164, A0A8V8TPE5, J3QSF7

UniProt curated annotations — full annotation on UniProt →

Function. Peroxidase that plays a central role in the host defense system of polymorphonuclear leukocytes by mediating both (1) formation of neutrophil extracellular trap (NETs) and (2) microbicidal activity. Promotes NET formation by mediating chromatin disassembly: translocates to the nucleus and specifically binds to nucleosomes, both as monomer and homodimer, leading to nucleosome unstacking and initial chromatin decondensation. Homodimers clash with one end of the nucleosomal DNA, leading to DNA unwrapping, initiating complete disassembly of nucleosomes and chromatin transformation into NETs in an ATP-independent manner. NETs, which are mainly composed of DNA fibers and globular proteins, are then extruded into the extracellular space by neutrophils to trap pathogens and release antimicrobial proteins to destroy them. Participates to the microbicidal activity against a wide range of organisms by acting as a peroxidase that catalyzes the formation of oxidants in presence of hydrogen peroxide. Mediates the formation of hypohalous acids, mainly hypochlorous acid (HOCl) in physiologic situations, that greatly enhance polymorphonuclear leukocyte microbicidal activity. In addition to hypochlorous acid, catalyzes formation of hypobromous acid (HOBr), hypoiodous acid (HOI) and hypothiocyanous acid (HOSCN). Also catalyzes oxidation of nitrite into the highly reactive nitrogen dioxide radical. Formation of oxidants are widely believed to be responsible for much of the anti-bactericidal activity of neutrophils. Oxidants, such as hypochlorous acid or nitrogen dioxide radical, can also oxidize amino acid residues on proteins and generate chlorination and nitration post-translational modifications, respectively. Chlorination and nitration of the lipid-free form of APOA1 impairs cholesterol transport. Superoxides generated by MPO can also promote dioxygenation of tryptophan residues on proteins. Also able to oxidize melatonin into N1-acetyl-N2-formyl-5-methoxykynuramine either in presence of hydrogen peroxide or superoxide. Oxidizes urate into 5-hydroxyisourate. Functions as a nitric oxide (NO) oxidase during inflammation, by catalytically consuming NO, impairing NO’s ability to maintain vascular tone and function. May also mediate the proteolytic cleavage of alpha-1-microglobulin to form t-alpha-1-microglobulin, which potently inhibits oxidation of low-density lipoprotein particles and limits vascular damage. Light chain of the mature myeloperoxidase. Heavy chain of the mature myeloperoxidase. (Microbial infection) The peroxidase activity is inhibited by S.aureus peroxidase inhibitor SPIN that blocks substrate access to the catalytic heme.

Subunit / interactions. Mature myeloperoxidase is a homodimer; disulfide-linked. Each monomer is composed of myeloperoxidase heavy chain and myeloperoxidase light chain. Interacts with CP (ceruloplasmin); inhibiting the peroxidase activity of MPO. Found in a complex with CP and LTF; protects CP antioxidant properties by MPO. Mature myeloperoxidase is a homodimer; disulfide-linked. Each monomer is composed of myeloperoxidase heavy chain and myeloperoxidase light chain. Mature myeloperoxidase is a homodimer; disulfide-linked. Each monomer is composed of myeloperoxidase heavy chain and myeloperoxidase light chain.

Subcellular location. Lysosome. Cytolytic granule. Cytoplasmic vesicle. Phagosome. Secreted. Nucleus. Chromosome.

Tissue specificity. Specifically expressed in neutrophils and monocytes.

Post-translational modifications. Mature myeloperoxidase is a homodimer linked by disulfide bond, with each monomer composed of a heavy and light chain. Myeloperoxidase encompasses a series of critical proteolytic processing steps during maturation: after cotranslational cleavage of the signal peptide and N-linked glycosylation followed by limited deglucosylation, myeloperoxidase acquires heme in the endoplasmic reticulum (ER) to form the 84 kDa myeloperoxidase (also named promyeloperoxidase). A proconvertase then eliminates the propeptide region (49-164) in a post-ER compartment producing an intermediate species that is subsequently processed by cysteine proteases to the light chain and heavy chain followed by homodimerization. Myeloperoxidase monomers are linked by an interchain disulfide bond at Cys-319. During maturation, the 84 kDa myeloperoxidase (also named promyeloperoxidase) precursor contains a disulfide bond between Cys-158 and Cys-319 that prevents homodimerization. N-glycosylated; all sites contain a fraction of paucimannose-type glycans. Asn-323 contains phosphorylated (probably mannose-6-phosphate) and paucimannose-type N-glycans. Asn-355 and Asn-391 primarily show high-mannose or paucimannose glycan-types without core-fucosylation, but are partially deglucosylated during maturation of the protein. Truncation of N-glycans leads to increased myeloperoxidase activity. Asn-483 contains paucimannose-type glycans, with abundant signals of sialylated complex glycans. Asn-729 only contains paucimannose-type glycans.

Disease relevance. Myeloperoxidase deficiency (MPOD) [MIM:254600] A disorder characterized by decreased myeloperoxidase activity in neutrophils and monocytes that results in disseminated candidiasis. The disease is caused by variants affecting the gene represented in this entry.

Activity regulation. The peroxidase activity is inhibited by CP (ceruloplasmin). The peroxidase activity is inhibited by 2-thioxanthines which form a covalent attachment with the heme group. Inhibited by 3-(2-ethoxypropyl)- 2-thioxo-2,3-dihydro-1H-purin-6(9H)-one, a derivative of 2-thioxanthine that couples with the heme group. Specifically inhibited by aromatic hydroxamates, such as trifluoromethyl-substituted aromatic hydroxamate HX1.

Cofactor. Binds 1 Ca(2+) ion per monomer. Binds 1 heme b (iron(II)-protoporphyrin IX) group covalently per monomer.

Similarity. Belongs to the peroxidase family. XPO subfamily.

Isoforms (3)

UniProt ID	Names	Canonical?
P05164-1	H17, B	yes
P05164-2	H14
P05164-3	H7, A

RefSeq proteins (1): NP_000241* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR010255	Haem_peroxidase_sf	Homologous_superfamily
IPR019791	Haem_peroxidase_animal	Family
IPR037120	Haem_peroxidase_sf_animal	Homologous_superfamily

Pfam: PF03098

Enzyme classification (BRENDA)

• EC 1.11.2.2 — myeloperoxidase (BRENDA: 9 organisms, 109 substrates, 246 inhibitors, 35 Km, 33 kcat entries)

Substrate kinetics (BRENDA)

21 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
1-ACETYL-4-(METHYLSULFANYL)BENZENE	0.016–0.039	2
1-CHLORO-4-(METHYLSULFANYL)BENZENE	0.027–0.067	2
1-METHOXY-4-(METHYLSULFANYL)BENZENE	0.012–0.03	2
1-METHYL-4-(METHYLSULFANYL)BENZENE	0.032–0.04	2
1-NITRO-4-(METHYLSULFANYL)BENZENE	0.066–0.076	2
3,4-DIHYDROXYPHENYLACETIC ACID	0.52–21.9	2
4-(METHYLSULFANYL)ANILINE	0.057–0.104	2
BENZOTHIOPHENE	0.072–0.081	2
BENZYL METHYL SULFIDE	0.05–0.083	2
CATECHOL	1.84–21.1	2
DOPAMINE	0.64–136.3	2
H2O2	0.03–0.07	2
PHENYL PROPAN-2-YL SULFIDE	0.026–0.041	2
SCN-	0.25–0.29	2
THIOANISOLE	0.018–0.02	2

Catalyzed reactions (Rhea)

• chloride + H2O2 + H(+) = hypochlorous acid + H2O (RHEA:28218)
• bromide + H2O2 = hypobromite + H2O (RHEA:66016)
• thiocyanate + H2O2 + H(+) = hypothiocyanous acid + H2O (RHEA:69416)
• iodide + H2O2 = hypoiodite + H2O (RHEA:69420)

UniProt features (124 total): helix 38, strand 21, turn 11, binding site 9, disulfide bond 8, sequence variant 8, chain 7, mutagenesis site 7, glycosylation site 6, site 2, splice variant 2, signal peptide 1, modified residue 1, propeptide 1, sequence conflict 1, active site 1

Structure

Experimental structures (PDB)

showing 30 of 49 structures by resolution:

PDB	Title	Method	Resolution (Å)
5MFA	Crystal structure of human promyeloperoxidase (proMPO)	X-RAY DIFFRACTION	1.2
5FIW	CRYSTAL STRUCTURE OF HUMAN MYELOPEROXIDASE AT 1.7 ANGSTROMS RESOLUTION	X-RAY DIFFRACTION	1.7
1D2V	CRYSTAL STRUCTURE OF BROMIDE-BOUND HUMAN MYELOPEROXIDASE ISOFORM C AT PH 5.5	X-RAY DIFFRACTION	1.75
1CXP	CRYOGENIC CRYSTAL STRUCTURE OF HUMAN MYELOPEROXIDASE ISOFORM C	X-RAY DIFFRACTION	1.8
1DNU	STRUCTURAL ANALYSES OF HUMAN MYELOPEROXIDASE-THIOCYANATE COMPLEX	X-RAY DIFFRACTION	1.85
1D5L	CRYSTAL STRUCTURE OF CYANIDE-BOUND HUMAN MYELOPEROXIDASE ISOFORM C AT PH 5.5	X-RAY DIFFRACTION	1.9
1D7W	CRYSTAL STRUCTURE OF HUMAN MYELOPEROXIDASE ISOFORM C COMPLEXED WITH CYANIDE AND BROMIDE …	X-RAY DIFFRACTION	1.9
1DNW	HUMAN MYELOPEROXIDASE-CYANIDE-THIOCYANATE COMPLEX	X-RAY DIFFRACTION	1.9
9QEX	Structure of native leukocyte myeloperoxidase in complex with a truncated version of the …	X-RAY DIFFRACTION	1.9
4C1M	Myeloperoxidase in complex with the revesible inhibitor HX1	X-RAY DIFFRACTION	2
4DL1	Crystal Structure of human Myeloperoxidase with covalent thioxanthine analog	X-RAY DIFFRACTION	2
9QE3	Structure of native leukocyte myeloperoxidase in complex with a truncated version of the …	X-RAY DIFFRACTION	2.06
6WY7	CRYSTAL STRUCTURE OF MYELOPEROXIDASE SUBFORM C (MPO) COMPLEX WITH Compound-41 A.K.A …	X-RAY DIFFRACTION	2.09
7NI3	CRYSTAL STRUCTURE OF NATIVE HUMAN MYELOPEROXIDASE IN COMPLEX WITH CPD 3	X-RAY DIFFRACTION	2.1
7NI1	CRYSTAL STRUCTURE OF NATIVE HUMAN MYELOPEROXIDASE IN COMPLEX WITH CPD 9	X-RAY DIFFRACTION	2.11
7QZR	Structure of native leukocyte myeloperoxidase in complex with the Staphyloccal Peroxidase …	X-RAY DIFFRACTION	2.18
9QJO	Structure of native leukocyte myeloperoxidase in complex with the Staphylococcal …	X-RAY DIFFRACTION	2.18
9QGA	Structure of native leukocyte myeloperoxidase in complex with a truncated version of the …	X-RAY DIFFRACTION	2.21
6WXZ	CRYSTAL STRUCTURE OF MYELOPEROXIDASE SUBFORM C (MPO) COMPLEX WITH Compound-29 A.K.A …	X-RAY DIFFRACTION	2.23
1MHL	CRYSTAL STRUCTURE OF HUMAN MYELOPEROXIDASE ISOFORM C CRYSTALLIZED IN SPACE GROUP P2(1) AT …	X-RAY DIFFRACTION	2.25
7LAN	CRYSTAL STRUCTURE OF MYELOPEROXIDASE SUBFORM C (MPO) COMPLEX WITH COMPOUND-30 AKA …	X-RAY DIFFRACTION	2.28
7Z53	Structure of native leukocyte myeloperoxidase in complex with a truncated version (SPIN …	X-RAY DIFFRACTION	2.28
6AZP	A Structurally Dynamic N-terminal Region Drives Function of the Staphylococcal Peroxidase …	X-RAY DIFFRACTION	2.29
3ZS0	Human Myeloperoxidase inactivated by TX2	X-RAY DIFFRACTION	2.3
5WDJ	CRYSTAL STRUCTURE OF MYELOPEROXIDASE SUBFORM C (MPO) COMPLEX WITH COMPOUND-6 AKA …	X-RAY DIFFRACTION	2.4
5UZU	Immune evasion by a Staphylococcal Peroxidase Inhibitor that blocks myeloperoxidase	X-RAY DIFFRACTION	2.4
6BMT	Crystal Structure of a Recombinant form of Human Myeloperoxidase Bound to an Inhibitor …	X-RAY DIFFRACTION	2.4
9SDS	Structure of native leukocyte myeloperoxidase in complex with a truncated version of the …	X-RAY DIFFRACTION	2.49
6WYD	CRYSTAL STRUCTURE OF MYELOPEROXIDASE SUBFORM C (MPO) COMPLEX WITH Compound-12 (AKA …	X-RAY DIFFRACTION	2.55
3ZS1	Human Myeloperoxidase inactivated by TX5	X-RAY DIFFRACTION	2.6

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P05164-F1	89.55	0.76

Human Protein Atlas

Protein class: Enzymes, ENZYME proteins, Oxidoreductases, Metabolic proteins, Predicted intracellular proteins, Plasma proteins, Cancer-related genes, Candidate cancer biomarkers, Mutated cancer genes, Candidate cardiovascular disease genes, Disease related genes, Potential drug targets, Human disease related genes, Primary immunodeficiency

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): vesicles; nucleoplasm

Antibody reliability (HPA): IH enhanced · IF supported

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3)

Position	Role
405	transition state stabilizer
409–410	cleavage; by autolysis
261	proton acceptor

Ligand- & substrate-binding residues (9)

Position	Role
260	heme b
262	Ca(2+)
334	Ca(2+)
336	Ca(2+)
338	Ca(2+)
340	Ca(2+)
408	heme b
409	heme b
502	heme b

Post-translational modifications (1)

Type	Positions
Cysteine sulfenic acid (-soh)	316

Disulfide bonds (8)

Type	Positions
Disulfide bond	158–319, 167–180, 281–291, 285–309, 387–398, 606–663, 704–730
Interchain	319

Glycosylation sites (6)

Type	Positions
N-linked (glcnac…) asparagine	139, 323, 355, 391, 483, 729

Mutagenesis-validated functional residues (7)

Position	Phenotype
129–136	prevents cleavage by subtilisin-like protases and maturation of myeloperoxidase.
129	prevents cleavage by subtilisin-like protases and maturation of myeloperoxidase. decreased peroxidase activity.
131	prevents cleavage by subtilisin-like protases and maturation of myeloperoxidase. does not affect the peroxidase activity.
135	prevents cleavage by subtilisin-like protases and maturation of myeloperoxidase. does not affect the peroxidase activity.
136	prevents cleavage by subtilisin-like protases and maturation of myeloperoxidase. does not affect the peroxidase activity.
260	impaired binding to heme b, leading to decreased peroxidase activity.
587	abolished interaction with h-502, leading to abolished peroxidase activity.

Function

Pathways and Gene Ontology

Reactome pathways

2 curated (TAS) of 5; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

5 pathways:

ID	Pathway	Evidence
R-HSA-8941413	Events associated with phagocytolytic activity of PMN cells	curated
R-HSA-6798695	Neutrophil degranulation	curated
R-HSA-168256	Immune System	—
R-HSA-168249	Innate Immune System	—
R-HSA-1222556	ROS and RNS production in phagocytes	—

MSigDB gene sets: 270 (showing top): VERHAAK_AML_WITH_NPM1_MUTATED_DN, MODULE_93, REACTOME_INNATE_IMMUNE_SYSTEM, GOCC_SECRETORY_GRANULE, GOBP_HYDROGEN_PEROXIDE_CATABOLIC_PROCESS, GOBP_SUPEROXIDE_METABOLIC_PROCESS, GOBP_RESPONSE_TO_FOOD, CHEOK_RESPONSE_TO_HD_MTX_UP, MODULE_16, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, MODULE_118, GOBP_REACTIVE_OXYGEN_SPECIES_BIOSYNTHETIC_PROCESS, GOBP_SMALL_MOLECULE_BIOSYNTHETIC_PROCESS, MODULE_75, GOBP_CELLULAR_RESPONSE_TO_TOXIC_SUBSTANCE

GO Biological Process (17): nucleosome disassembly (GO:0006337), defense response (GO:0006952), response to oxidative stress (GO:0006979), response to mechanical stimulus (GO:0009612), response to food (GO:0032094), response to lipopolysaccharide (GO:0032496), low-density lipoprotein particle remodeling (GO:0034374), defense response to bacterium (GO:0042742), hydrogen peroxide catabolic process (GO:0042744), negative regulation of apoptotic process (GO:0043066), neutrophil-mediated killing of symbiont cell (GO:0070943), neutrophil-mediated killing of bacterium (GO:0070944), neutrophil-mediated killing of fungus (GO:0070947), neutrophil extracellular trap formation (GO:0140645), response to gold nanoparticle (GO:1990268), cellular oxidant detoxification (GO:0098869), positive regulation of cholesterol import (GO:1904109)

GO Molecular Function (9): chromatin binding (GO:0003682), peroxidase activity (GO:0004601), heparin binding (GO:0008201), heme binding (GO:0020037), nucleosome binding (GO:0031491), metal ion binding (GO:0046872), protein-containing complex destabilizing activity (GO:0140776), protein binding (GO:0005515), oxidoreductase activity (GO:0016491)

GO Cellular Component (10): extracellular region (GO:0005576), nucleus (GO:0005634), lysosome (GO:0005764), secretory granule (GO:0030141), azurophil granule lumen (GO:0035578), azurophil granule (GO:0042582), phagocytic vesicle (GO:0045335), extracellular exosome (GO:0070062), phagocytic vesicle lumen (GO:0097013), neutrophil extracellular trap (GO:0140644)

Reactome top-level categories

3 top-level categories:

Category	Pathways
Innate Immune System	2
ROS and RNS production in phagocytes	1
Immune System	1

GO top-level categories

55 GO namespaces:

Category	Terms
response to stress	2
neutrophil-mediated killing of symbiont cell	2
binding	2
protein-DNA complex disassembly	1
nucleosome organization	1
response to external stimulus	1
response to abiotic stimulus	1
response to nutrient levels	1
response to chemical	1
response to molecule of bacterial origin	1
response to lipid	1
response to oxygen-containing compound	1
plasma lipoprotein particle remodeling	1
defense response	1
response to bacterium	1
catabolic process	1
hydrogen peroxide metabolic process	1
apoptotic process	1
regulation of apoptotic process	1
negative regulation of programmed cell death	1
killing of cells of another organism	1
neutrophil mediated cytotoxicity	1
defense response to bacterium	1
defense response to fungus	1
cellular component assembly	1
response to transition metal nanoparticle	1
cellular detoxification	1
positive regulation of cholesterol transport	1
regulation of cholesterol import	1
cholesterol import	1
antioxidant activity	1
oxidoreductase activity, acting on peroxide as acceptor	1
glycosaminoglycan binding	1
sulfur compound binding	1
tetrapyrrole binding	1
chromatin binding	1
protein-containing complex binding	1
cation binding	1
molecular_function	1
catalytic activity	1
cellular anatomical structure	1
intracellular membrane-bounded organelle	1
lytic vacuole	1
endomembrane system	1
secretory vesicle	1
vacuolar lumen	1
secretory granule lumen	1
azurophil granule	1
primary lysosome	1
secretory granule	1
endocytic vesicle	1
extracellular vesicle	1
phagocytic vesicle	1
endocytic vesicle lumen	1
extracellular membraneless organelle	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 17 of 37 annotations. The rest are phylogenetic / computational / electronic (IEA).

17 experimentally-supported GO terms:

GO term	NS	Evidence
hydrogen peroxide catabolic process	BP	direct assay
low-density lipoprotein particle remodeling	BP	direct assay
neutrophil extracellular trap formation	BP	direct assay
neutrophil-mediated killing of bacterium	BP	direct assay
neutrophil-mediated killing of fungus	BP	direct assay
neutrophil-mediated killing of symbiont cell	BP	direct assay
nucleosome disassembly	BP	direct assay
azurophil granule	CC	direct assay
extracellular exosome	CC	high-throughput assay
neutrophil extracellular trap	CC	direct assay
nucleus	CC	direct assay
phagocytic vesicle	CC	direct assay
secretory granule	CC	direct assay
heparin binding	MF	direct assay
nucleosome binding	MF	direct assay
peroxidase activity	MF	direct assay
protein-containing complex destabilizing activity	MF	direct assay

Protein interactions and networks

STRING

showing 15 of 3,026 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MPO	ELANE	P08246	936
MPO	PRTN3	P15637	913
MPO	IL6	P05231	865
MPO	CTSG	P08311	861
MPO	LTF	P02788	841
MPO	IL1B	P01584	840
MPO	IL10	P22301	816
MPO	TNF	P01375	805
MPO	CRP	P02741	797
MPO	CD68	P34810	792
MPO	F5H3C5	F5H3C5	783
MPO	IFNG	P01579	767
MPO	PADI4	Q9UM07	757
MPO	CSF3	P09919	746
MPO	TLR4	O00206	744

IntAct

Human interaction partners of MPO in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

16 partners by confidence:

Partner	Interaction type	MIscore	Records
CALR	direct interaction	0.580	3
STUB1	physical association	0.560	3
CFP	direct interaction	0.540	1
EGFL8	association	0.530	1
C3	physical association	0.400	2
C9	physical association	0.400	1
CCDC47	physical association	0.400	1
GYPA	physical association	0.400	1
GYPB	physical association	0.400	1
HNRNPK	physical association	0.400	1
SLC4A1	physical association	0.400	1
C9orf85	association	0.350	1
HS1BP3	association	0.350	1
MAEA	association	0.350	1
MNAT1	association	0.350	1
PTEN	proximity	0.270	1

BioGRID (60 interactions; top human partners by supporting records): ICE2 (Affinity Capture-MS; 3 records), APCDD1 (Affinity Capture-MS; 2 records), FRMD1 (Affinity Capture-MS; 2 records), PLB1 (Affinity Capture-MS; 2 records), AGPAT1 (Affinity Capture-MS), ALB (Co-fractionation), CAT (Co-fractionation), CCR1 (Affinity Capture-MS), CEBPA (Protein-peptide), CLCN2 (Affinity Capture-MS), CYP3A43 (Affinity Capture-MS), EGFL8 (Affinity Capture-MS), ELANE (Co-fractionation), ERO1L (Affinity Capture-MS), ESR2 (Affinity Capture-MS)

SIGNOR signaling

3 signaling interactions:

A	Effect	B	Mechanism
KRT1	“up-regulates quantity”	MPO	binding
MPO	“down-regulates activity”	APOA1	oxidation
MPO	“up-regulates activity”	MPO-ANCA	binding

Protein complexes (CORUM) (2)

Experimentally-characterized complexes this protein is a subunit of (★ = the complex contains a known drug target).

2 complexes by size:

Complex	Subunits	Members
CP-LTF-MPO complex	3	LTF, MPO, CP
CP-MPO complex	2	CP, MPO

Disease & clinical

Genetic variants

Variant evidence for MPO: 101 ClinVar records (6 pathogenic / likely pathogenic); 32 GWAS associations. Per-variant detail is on Sugi Variant.

ClinVar

101 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	5
Uncertain significance	61
Likely benign	22
Benign	2

Top pathogenic / likely-pathogenic (6)

Showing all 6 pathogenic / likely-pathogenic ClinVar records, ranked by ClinVar review status (expert panel → multiple submitters → single submitter), then by number of submitting labs.

Variant ID	HGVS	Classification	Review	Submitters
452644	NM_000250.2(MPO):c.1281del (p.Thr428fs)	Likely pathogenic	criteria provided, multiple submitters, no conflicts	3
4845803	NM_000250.2(MPO):c.1805G>A (p.Trp602Ter)	Likely pathogenic	criteria provided, multiple submitters, no conflicts	2
4857469	NM_000250.2(MPO):c.625_626del (p.Leu209fs)	Pathogenic	criteria provided, single submitter	1
3779889	NM_000250.2(MPO):c.817dup (p.Ala273fs)	Likely pathogenic	criteria provided, single submitter	1
3893371	NM_000250.2(MPO):c.760_764del (p.Gln254fs)	Likely pathogenic	criteria provided, single submitter	1
3351076	NM_000250.2(MPO):c.604dup (p.Glu202fs)	Likely pathogenic	no assertion criteria provided	1

Per-variant reference — Sugi Variant

Explore MPO’s pathogenic and likely-pathogenic variants individually — each with its ClinVar classification and conditions, applied ACMG criteria (ClinGen expert panel, where curated), the calibrated in-silico predictors (AlphaMissense, REVEL, SaProt, conservation), gnomAD frequency, and the predictor-disagreement QC signal — on Sugi Variant.

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 31 predictions of 928):

Position(s)	Effect	Δscore	Sites
17:58271893–58271894	acceptor_loss	1.0000	2
17:58272746–58272747	donor_loss	1.0000	5
17:58272919–58272920	acceptor_loss	1.0000	5
17:58275704	acceptor_gain	1.0000
17:58277826	donor_loss	1.0000	2
17:58279006–58279007	donor_loss	1.0000	3
17:58279041	donor_gain	1.0000
17:58279215–58279216	acceptor_loss	1.0000	6
17:58279537	donor_gain	1.0000
17:58279647–58279648	acceptor_loss	1.0000	5

AlphaMissense

1,810 missense substitutions predicted likely pathogenic (of 4,867 scored), across 442 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
D582	8	0.995	0.997
H261	8	0.993	0.998
D300	8	0.985	0.993
H502	8	0.985	0.993
D403	8	0.984	0.997
H423	8	0.984	0.990
D338	8	0.981	0.992
F573	8	0.977	0.997
D676	8	0.974	0.990
D262	8	0.972	0.992
D593	8	0.971	0.997
F494	8	0.961	0.997
D641	8	0.957	0.989
H594	8	0.954	0.991
D260	8	0.950	0.988
F686	8	0.940	0.986
F718	8	0.936	0.982
F399	8	0.933	0.985
D245	8	0.929	0.953
N424	8	0.923	0.989

HPA cancer prognostics

RNA cancer specificity: Cancer enhanced (Stomach Adenocarcinoma)

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

1 prognostic cancer types:

Cancer	Prognostic	p-value
Stomach Adenocarcinoma (TCGA)	unfavorable	0.000787

Disease associations

OMIM: gene MIM:606989 | disease phenotypes: MIM:254600

GenCC curated gene-disease

1 curated gene-disease records:

Disease	Classification	Inheritance	Records
myeloperoxidase deficiency	Moderate	Autosomal recessive

Genomics England panels (PanelApp)

Clinical diagnostic gene panels including this gene (2 panels, 1 green/diagnostic-grade). Confidence: green = diagnostic, amber = moderate.

2 panels:

Panel	Rating
COVID-19 research	green
Primary immunodeficiency or monogenic inflammatory bowel disease	amber

Mondo (1): myeloperoxidase deficiency (MONDO:0009694)

Orphanet (1): Myeloperoxidase deficiency (Orphanet:2587)

HPO phenotypes

14 phenotypes (HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000007	Autosomal recessive inheritance
HP:0000726	Dementia
HP:0001300	Parkinsonism
HP:0001871	Abnormality of blood and blood-forming tissues
HP:0001939	Abnormality of metabolism/homeostasis
HP:0002185	Neurofibrillary tangles
HP:0002423	Long-tract sign
HP:0002511	Alzheimer disease
HP:0002715	Abnormality of the immune system
HP:0003581	Adult onset
HP:0410054	Decreased circulating GABA concentration
HP:6000375	Reduced neutrophil myeloperoxidase activity
HP:6000513	Diminished neutrophil myeloperoxidase activity

GWAS associations

showing 30 of 32 associations:

Study	Trait	p-value
GCST90002394_402	Monocyte percentage of white cells	7e-71
GCST004609_148	Monocyte percentage of white cells	4e-63
GCST004608_200	Granulocyte percentage of myeloid white cells	9e-57
GCST90002393_199	Monocyte count	9e-50
GCST004625_244	Monocyte count	8e-41
GCST90002394_399	Monocyte percentage of white cells	2e-31
GCST90002379_85	Basophil count	3e-30
GCST90002399_332	Neutrophil percentage of white cells	5e-30
GCST90002380_104	Basophil percentage of white cells	5e-26
GCST90002379_84	Basophil count	3e-23
GCST004620_114	Sum basophil neutrophil counts	2e-18
GCST004629_107	Neutrophil count	2e-18
GCST90002398_393	Neutrophil count	9e-18
GCST004613_26	Sum neutrophil eosinophil counts	3e-17
GCST90002394_401	Monocyte percentage of white cells	3e-17
GCST004626_12	Myeloid white cell count	4e-17
GCST004614_11	Granulocyte count	6e-17
GCST90002407_635	White blood cell count	2e-16
GCST009731_51	Blood protein levels in cardiovascular risk	5e-16
GCST004633_120	Neutrophil percentage of white cells	2e-15
GCST004610_25	White blood cell count	9e-13
GCST90002389_260	Lymphocyte percentage of white cells	1e-12
GCST90002393_197	Monocyte count	5e-12
GCST90002399_334	Neutrophil percentage of white cells	2e-11
GCST90002398_395	Neutrophil count	2e-10
GCST90002394_400	Monocyte percentage of white cells	3e-10
GCST90002380_103	Basophil percentage of white cells	7e-10
GCST90002393_198	Monocyte count	2e-9
GCST90002399_333	Neutrophil percentage of white cells	2e-9
GCST001980_2	Circulating myeloperoxidase levels (plasma)	4e-9

EFO canonical traits (from GWAS)

12 canonical traits:

EFO ID	Trait name
EFO:0005243	myeloperoxidase measurement
EFO:0004713	FEV/FVC ratio
EFO:0007997	granulocyte percentage of myeloid white cells
EFO:0007989	monocyte percentage of leukocytes
EFO:0004833	neutrophil count
EFO:0004842	eosinophil count
EFO:0007987	granulocyte count
EFO:0005090	basophil count
EFO:0005091	monocyte count
EFO:0007990	neutrophil percentage of leukocytes
EFO:0007992	basophil percentage of leukocytes
EFO:0007993	lymphocyte percentage of leukocytes

MeSH disease descriptors

1 disease descriptors:

Descriptor	Name	Tree numbers
C562864	Myeloperoxidase Deficiency *(supp.)*

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2439 (SINGLE PROTEIN)

Drugs by curated mechanism of action (ChEMBL)

Drugs whose curated ChEMBL mechanism of action targets the MPO protein itself — single-protein targets only (drugs acting on a protein family or complex that merely includes it are excluded). Includes antibodies and oligonucleotides that bioactivity screening does not capture.

1 curated-mechanism drugs:

Drug	Modality	Max phase
VERDIPERSTAT	Small molecule	3

Molecules with ChEMBL bioactivity

Phase ≥1, by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,179,323 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

19 molecules by phase:

Molecule	Name	Phase	Patents
CHEMBL1043	DAPSONE	4	65,329
CHEMBL276832	HYDRALAZINE	4	23,974
CHEMBL64	ISONIAZID	4	145,747
CHEMBL686	MEFENAMIC ACID	4	62,458
CHEMBL45	MELATONIN	4	57,288
CHEMBL86	METOCLOPRAMIDE	4	38,126
CHEMBL56367	NIMESULIDE	4	25,616
CHEMBL490	PAROXETINE	4	46,771
CHEMBL1518	PROPYLTHIOURACIL	4	15,154
CHEMBL54976	TRYPTOPHAN	4	555,773
CHEMBL4297594	VERDIPERSTAT	3	141
CHEMBL50	QUERCETIN	3	75,572
CHEMBL23588	FLUFENAMIC ACID	2	35,023
CHEMBL2105120	FTIVAZIDE	2	118
CHEMBL267044	LEVOSULPIRIDE	2	4,291
CHEMBL5095218	MITIPERSTAT	2	57
CHEMBL1232461	MOLIBRESIB	2	1,601
CHEMBL150	KAEMPFEROL	1	26,246
CHEMBL3633460	PF-06282999	1	38

PharmGKB: 1 entry (CPIC guideline: no)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — Oxidoreductases

Most potent curated ligand interactions (6 total), top 6:

Ligand	Action	Affinity	Parameter
mitiperstat	Inhibition	9.15	pIC50
compound 28 [PMID: 28671460]	Inhibition	7.36	pIC50
aminopyridine 2	Inhibition	6.8	pIC50
AZD5904	Inhibition	6.7	pIC50
PF-06282999	Inhibition	6.5	pKi
verdiperstat	Inhibition	6.2	pIC50

Binding affinities (BindingDB)

621 measured of 730 human assays (753 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
1-[[2-[(2S,4R)-4-(difluoromethyl)piperidin-2-yl]phenyl]methyl]-2-sulfanylidene-5,6,7,7a-tetrahydro-4aH-pyrrolo[3,2-d]pyrimidin-4-one	IC50	1 nM	US-20240166642: INHIBITORS OF MYELOPEROXIDASE
2-sulfanylidene-1-[[2-[(2R,4S)-4-(trifluoromethyl)piperidin-2-yl]phenyl]methyl]-5,6,7,7a-tetrahydro-4aH-pyrrolo[3,2-d]pyrimidin-4-one	IC50	1.5 nM	US-20240166642: INHIBITORS OF MYELOPEROXIDASE
CHEMBL4763667	IC50	2 nM
1-[[2-[(2S)-piperidin-2-yl]phenyl]methyl]-2-sulfanylidene-5,6,7,7a-tetrahydro-4aH-pyrrolo[3,2-d]pyrimidin-4-one	IC50	2 nM	US-20240166642: INHIBITORS OF MYELOPEROXIDASE
2-sulfanylidene-3-[[2-[(2S,4R)-4-(trifluoromethyl)piperidin-2-yl]phenyl]methyl]-5,7,8,9-tetrahydro-4H-purin-6-one	IC50	2 nM	US-20240166642: INHIBITORS OF MYELOPEROXIDASE
1-[[2-[(2S)-4,4-difluoropiperidin-2-yl]phenyl]methyl]-2-sulfanylidene-5,6,7,7a-tetrahydro-4aH-pyrrolo[3,2-d]pyrimidin-4-one	IC50	2.7 nM	US-20240166642: INHIBITORS OF MYELOPEROXIDASE
2-sulfanylidene-3-[[2-[(2R,4R)-4-(trifluoromethyl)piperidin-2-yl]phenyl]methyl]-5,7,8,9-tetrahydro-4H-purin-6-one	IC50	2.7 nM	US-20240166642: INHIBITORS OF MYELOPEROXIDASE
1-[[2-[(2S)-azepan-2-yl]phenyl]methyl]-2-sulfanylidene-5,6,7,7a-tetrahydro-4aH-pyrrolo[3,2-d]pyrimidin-4-one	IC50	2.8 nM	US-20240166642: INHIBITORS OF MYELOPEROXIDASE
CHEMBL4752248	IC50	2.9 nM
CHEMBL2347170	IC50	3 nM
1-[[4-chloro-2-[(2R)-pyrrolidin-2-yl]phenyl]methyl]-2-sulfanylidene-5,6,7,7a-tetrahydro-4aH-pyrrolo[3,2-d]pyrimidin-4-one	IC50	3 nM	US-20240166642: INHIBITORS OF MYELOPEROXIDASE
1-[(2-piperidin-3-ylphenyl)methyl]-2-sulfanylidene-5,6,7,7a-tetrahydro-4aH-pyrrolo[3,2-d]pyrimidin-4-one	IC50	3 nM	US-20240166642: INHIBITORS OF MYELOPEROXIDASE
2-sulfanylidene-1-[[2-[(2S,4S)-4-(trifluoromethyl)piperidin-2-yl]phenyl]methyl]-5,6,7,7a-tetrahydro-4aH-pyrrolo[3,2-d]pyrimidin-4-one	IC50	3.4 nM	US-20240166642: INHIBITORS OF MYELOPEROXIDASE
1-[[4-chloro-2-[(2S)-piperidin-2-yl]phenyl]methyl]-2-sulfanylidene-5,6,7,7a-tetrahydro-4aH-pyrrolo[3,2-d]pyrimidin-4-one	IC50	3.6 nM	US-20240166642: INHIBITORS OF MYELOPEROXIDASE
2-sulfanylidene-1-[[2-[(2R,4S)-4-(trifluoromethyl)piperidin-2-yl]-3-pyridinyl]methyl]-5,6,7,7a-tetrahydro-4aH-pyrrolo[3,2-d]pyrimidin-4-one	IC50	3.9 nM	US-20240166642: INHIBITORS OF MYELOPEROXIDASE
CHEMBL2347168	IC50	4 nM
7-[(2,6-dichlorophenyl)methylsulfanyl]-2H-triazolo[4,5-b]pyridin-5-amine	IC50	4.6 nM	US-10981879: Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase
7-[(3R,4S,6S,10S)-4-benzyl-2-oxa-7,13,14-triazatetracyclo[14.3.1.13,6.111,14]docosa-1(19),11(21),12,16(20),17-pentaen-10-yl]-2H-triazolo[4,5-b]pyridin-5-amine	IC50	5 nM	US-10577383: Macrocyclic inhibitors of myeloperoxidase
CHEMBL4068067	IC50	5 nM
5-(5-fluoro-1H-indol-3-yl)pentan-1-amine	IC50	5 nM
CHEMBL4740830	IC50	5 nM
CHEMBL5197968	IC50	5 nM
1-[[3-(1-aminocyclobutyl)phenyl]methyl]-2-sulfanylidene-5,6,7,7a-tetrahydro-4aH-pyrrolo[3,2-d]pyrimidin-4-one	IC50	5 nM	US-20240166642: INHIBITORS OF MYELOPEROXIDASE
2-sulfanylidene-1-[[3-[(2R,4S)-4-(trifluoromethyl)piperidin-2-yl]-2-pyridinyl]methyl]-5,6,7,7a-tetrahydro-4aH-pyrrolo[3,2-d]pyrimidin-4-one	IC50	5.7 nM	US-20240166642: INHIBITORS OF MYELOPEROXIDASE
CHEMBL4782307	IC50	6 nM
2-sulfanylidene-1-[[2-[(2S,4R)-4-(trifluoromethyl)piperidin-2-yl]phenyl]methyl]-5,6,7,7a-tetrahydro-4aH-pyrrolo[3,2-d]pyrimidin-4-one	IC50	6 nM	US-20240166642: INHIBITORS OF MYELOPEROXIDASE
CHEMBL4453728	IC50	6.7 nM
1-[2-(1-Aminoethyl)-4-chlorobenzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one	IC50	7 nM	US-10016430: 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
CHEMBL4855931	IC50	7.1 nM
3-[[2-(azepan-2-yl)-4-chlorophenyl]methyl]-2-sulfanylidene-5,7,8,9-tetrahydro-4H-purin-6-one	IC50	7.1 nM	US-20240166642: INHIBITORS OF MYELOPEROXIDASE
3-[[2-(4,4-difluoropiperidin-2-yl)phenyl]methyl]-2-sulfanylidene-5,7,8,9-tetrahydro-4H-purin-6-one	IC50	7.2 nM	US-20240166642: INHIBITORS OF MYELOPEROXIDASE
US10407422, Example 130	IC50	8 nM	US-10407422: Triazolopyridine inhibitors of myeloperoxidase
1-{2-[(1R)-1-Aminopropyl]-4-chlorobenzyl}-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one	IC50	8.6 nM	US-10016430: 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
CHEMBL4751166	IC50	9.3 nM
1-{2-[(Cyclobutylamino)methyl]benzyl}-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one	IC50	10 nM	US-10016430: 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
7-(1-phenylethylsulfanyl)-2H-triazolo[4,5-b]pyridin-5-amine	IC50	10 nM	US-10981879: Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase
7-[[2,5-difluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methylsulfanyl]-2H-triazolo[4,5-b]pyridin-5-amine	IC50	10 nM	US-10981879: Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase
7-[[2,5-bis(trifluoromethyl)phenyl]methylsulfanyl]-2H-triazolo[4,5-b]pyridin-5-amine	IC50	10 nM	US-10981879: Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase
7-[[5-fluoro-2-(trifluoromethoxy)phenyl]methylsulfanyl]-2H-triazolo[4,5-b]pyridin-5-amine	IC50	10 nM	US-10981879: Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase
7-[(2-chloro-4-methylsulfonylphenyl)methylsulfanyl]-2H-triazolo[4,5-b]pyridin-5-amine	IC50	10 nM	US-10981879: Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase
7-[[1-phenyl-3-(trifluoromethyl)pyrazol-4-yl]methylsulfanyl]-2H-triazolo[4,5-b]pyridin-5-amine	IC50	10 nM	US-10981879: Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase
7-[[1-(6-pyrrolidin-1-yl-3-pyridinyl)-3-(trifluoromethyl)pyrazol-4-yl]methylsulfanyl]-2H-triazolo[4,5-b]pyridin-5-amine	IC50	10 nM	US-10981879: Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase
CHEMBL2347167	IC50	10 nM
CHEMBL2347166	IC50	10 nM
2-sulfanylidene-1-(1,2,3,4-tetrahydroisoquinolin-8-ylmethyl)-5,6,7,7a-tetrahydro-4aH-pyrrolo[3,2-d]pyrimidin-4-one	IC50	10 nM	US-20240166642: INHIBITORS OF MYELOPEROXIDASE
1-[[2-(4-methylpiperazin-2-yl)phenyl]methyl]-2-sulfanylidene-5,6,7,7a-tetrahydro-4aH-pyrrolo[3,2-d]pyrimidin-4-one	IC50	10.1 nM	US-20240166642: INHIBITORS OF MYELOPEROXIDASE
US10407422, Example 5	IC50	11 nM	US-10407422: Triazolopyridine inhibitors of myeloperoxidase
CHEMBL2347176	IC50	11 nM
CHEMBL4862053	IC50	11 nM
2-sulfanylidene-1-[[3-[(2R,4S)-4-(trifluoromethyl)piperidin-2-yl]-4-pyridinyl]methyl]-5,6,7,7a-tetrahydro-4aH-pyrrolo[3,2-d]pyrimidin-4-one	IC50	11.5 nM	US-20240166642: INHIBITORS OF MYELOPEROXIDASE

ChEMBL bioactivities

936 potent at pChembl≥5 of 966 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.00	IC50	1	nM	CHEMBL4747269
9.00	IC50	1	nM	CHEMBL4790231
9.00	IC50	1	nM	CHEMBL5639106
8.90	IC50	1.259	nM	CHEMBL5197968
8.85	IC50	1.4	nM	CHEMBL4790231
8.82	IC50	1.5	nM	MITIPERSTAT
8.80	IC50	1.585	nM	MITIPERSTAT
8.70	IC50	2	nM	CHEMBL4763667
8.70	IC50	2	nM	CHEMBL5641842
8.70	IC50	2	nM	CHEMBL5646914
8.70	IC50	2	nM	CHEMBL5646667
8.54	IC50	2.9	nM	CHEMBL4752248
8.52	IC50	3	nM	CHEMBL2347170
8.52	IC50	3	nM	CHEMBL5641725
8.52	IC50	3	nM	CHEMBL5640015
8.44	IC50	3.6	nM	CHEMBL5181350
8.40	IC50	4	nM	CHEMBL2347168
8.34	IC50	4.6	nM	CHEMBL4548537
8.30	IC50	5	nM	CHEMBL2347177
8.30	IC50	5	nM	CHEMBL4068067
8.30	IC50	5	nM	CHEMBL1630742
8.30	IC50	5	nM	CHEMBL4740830
8.30	IC50	5	nM	CHEMBL4861370
8.30	IC50	5	nM	CHEMBL5197968
8.22	IC50	6	nM	CHEMBL2347170
8.22	IC50	6	nM	CHEMBL2347032
8.22	IC50	6	nM	CHEMBL4782307
8.17	IC50	6.7	nM	CHEMBL4453728
8.17	IC50	6.8	nM	CHEMBL4482878
8.15	IC50	7	nM	CHEMBL4851535
8.15	IC50	7	nM	CHEMBL5936050
8.15	IC50	7	nM	MITIPERSTAT
8.15	IC50	7	nM	CHEMBL4482878
8.15	IC50	7	nM	CHEMBL5796857
8.10	IC50	8	nM	CHEMBL2347168
8.10	IC50	8	nM	CHEMBL1630741
8.10	IC50	8	nM	CHEMBL4878307
8.10	IC50	8	nM	CHEMBL5924076
8.10	IC50	8	nM	CHEMBL1630742
8.07	IC50	8.5	nM	CHEMBL4594116
8.07	IC50	8.6	nM	CHEMBL5897801
8.06	IC50	8.7	nM	CHEMBL4482878
8.05	IC50	9	nM	CHEMBL4278946
8.05	IC50	9	nM	CHEMBL5794368
8.03	IC50	9.3	nM	CHEMBL4751166
8.00	IC50	10	nM	CHEMBL2347167
8.00	IC50	10	nM	CHEMBL2347166
8.00	IC50	10	nM	CHEMBL5999011
8.00	IC50	10	nM	CHEMBL5892400
8.00	IC50	10	nM	CHEMBL4482878

PubChem BioAssay actives

481 with measured affinity, of 1175 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
7-[(1R)-1-phenyl-3-[[(1S,3S)-3-phenyl-2,3-dihydro-1H-inden-1-yl]amino]propyl]-2H-triazolo[4,5-b]pyridin-5-amine	1698296: Inhibition of recombinant human MPO incubated for 10 mins in presence of 120 mM NaCl by aminophenyl fluorescein based assay	ic50	0.0010	uM
7-[(1R)-1-phenyl-3-[(4-phenyl-1-bicyclo[2.2.2]octanyl)amino]propyl]-2H-triazolo[4,5-b]pyridin-5-amine	1753665: Inhibition of MPO (unknown origin) chlorination activity incubated for 10 mins followed by NaCl addition by aminophenyl fluorescein assay	ic50	0.0010	uM
1-[[2-[(2S,4R)-4-(difluoromethyl)piperidin-2-yl]phenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one	2144486: Inhibition of human MPO using H2O2 as substrate measured after 15 mins by chemiluminescence based assay	ic50	0.0010	uM
1-[[2-[amino(phenyl)methyl]phenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one	1875005: Inhibition of MPO (unknown origin) measured after 15 mins in presence of H2O2 by chemiluminescence assay	ic50	0.0013	uM
1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one	1875005: Inhibition of MPO (unknown origin) measured after 15 mins in presence of H2O2 by chemiluminescence assay	ic50	0.0015	uM
7-[(1R)-1-phenyl-3-[(4-phenylcyclohexyl)amino]propyl]-2H-triazolo[4,5-b]pyridin-5-amine	1698296: Inhibition of recombinant human MPO incubated for 10 mins in presence of 120 mM NaCl by aminophenyl fluorescein based assay	ic50	0.0020	uM
2-sulfanylidene-1-[[2-[(2R,4S)-4-(trifluoromethyl)piperidin-2-yl]phenyl]methyl]-5H-pyrrolo[3,2-d]pyrimidin-4-one	2144486: Inhibition of human MPO using H2O2 as substrate measured after 15 mins by chemiluminescence based assay	ic50	0.0020	uM
2-sulfanylidene-3-[[2-[(2S,4R)-4-(trifluoromethyl)piperidin-2-yl]phenyl]methyl]-7H-purin-6-one	2144486: Inhibition of human MPO using H2O2 as substrate measured after 15 mins by chemiluminescence based assay	ic50	0.0020	uM
1-[[2-[(2S)-piperidin-2-yl]phenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one	2144486: Inhibition of human MPO using H2O2 as substrate measured after 15 mins by chemiluminescence based assay	ic50	0.0020	uM
7-[(1R)-1-phenyl-3-[[(1R,4S)-4-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl]amino]propyl]-2H-triazolo[4,5-b]pyridin-5-amine	1698296: Inhibition of recombinant human MPO incubated for 10 mins in presence of 120 mM NaCl by aminophenyl fluorescein based assay	ic50	0.0029	uM
2-sulfanylidene-3-[[2-[(2R,4R)-4-(trifluoromethyl)piperidin-2-yl]phenyl]methyl]-7H-purin-6-one	2144486: Inhibition of human MPO using H2O2 as substrate measured after 15 mins by chemiluminescence based assay	ic50	0.0030	uM
1-[[2-[(2S)-4,4-difluoropiperidin-2-yl]phenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one	2144486: Inhibition of human MPO using H2O2 as substrate measured after 15 mins by chemiluminescence based assay	ic50	0.0030	uM
2-[2-(7-fluoro-1H-indol-3-yl)ethylsulfanyl]ethanamine	738129: Inhibition of human recombinant MPO-mediated taurine chlorination after 5 mins by microplate assay	ic50	0.0030	uM
3-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-7H-purin-6-one	1875005: Inhibition of MPO (unknown origin) measured after 15 mins in presence of H2O2 by chemiluminescence assay	ic50	0.0036	uM
2-[2-(5-fluoro-1H-indol-3-yl)ethylsulfanyl]ethanamine	738129: Inhibition of human recombinant MPO-mediated taurine chlorination after 5 mins by microplate assay	ic50	0.0040	uM
7-[(2,6-dichlorophenyl)methylsulfanyl]-2H-triazolo[4,5-b]pyridin-5-amine	1533019: Inhibition of human PMN leukocytes MPO peroxidation activity using H2O2 as substrate preincubated for 10 mins followed by H2O2 addition and measured for 15 mins by amplex red reagent based assay	ic50	0.0046	uM
2-[[3,5-bis(trifluoromethyl)phenyl]methylamino]-N-hydroxy-4-oxo-1,3-diazinane-5-carboxamide	1802478: Myeloperoxidase Assay from Article 10.1074/jbc.M113.507756: “Potent reversible inhibition of myeloperoxidase by aromatic hydroxamates.”	ic50	0.0050	uM
7-[(3R,4S,6S,10S)-4-benzyl-2-oxa-7,13,14-triazatetracyclo[14.3.1.13,6.111,14]docosa-1(19),11(21),12,16(20),17-pentaen-10-yl]-2H-triazolo[4,5-b]pyridin-5-amine	1753665: Inhibition of MPO (unknown origin) chlorination activity incubated for 10 mins followed by NaCl addition by aminophenyl fluorescein assay	ic50	0.0050	uM
7-[(1R)-3-[2-fluoroethyl-(4-phenyl-1-bicyclo[2.2.2]octanyl)amino]-1-phenylpropyl]-2H-triazolo[4,5-b]pyridin-5-amine	1698296: Inhibition of recombinant human MPO incubated for 10 mins in presence of 120 mM NaCl by aminophenyl fluorescein based assay	ic50	0.0050	uM
5-(5-fluoro-1H-indol-3-yl)pentan-1-amine	1446226: Inhibition of recombinant MPO (unknown origin) assessed as reduction in taurine chloramine production preincubated with enzyme and taurine followed by H2O2 addition measured after 5 mins	ic50	0.0050	uM
3-(5-fluoro-1H-indol-3-yl)propyl thiocyanate	738129: Inhibition of human recombinant MPO-mediated taurine chlorination after 5 mins by microplate assay	ic50	0.0050	uM
2-[[3,5-bis(trifluoromethyl)phenyl]methylamino]-N-hydroxy-6-oxo-1H-pyrimidine-5-carboxamide	1446226: Inhibition of recombinant MPO (unknown origin) assessed as reduction in taurine chloramine production preincubated with enzyme and taurine followed by H2O2 addition measured after 5 mins	ic50	0.0050	uM
7-[(1R)-3-[methyl-(4-phenyl-1-bicyclo[2.2.2]octanyl)amino]-1-phenylpropyl]-2H-triazolo[4,5-b]pyridin-5-amine	1698296: Inhibition of recombinant human MPO incubated for 10 mins in presence of 120 mM NaCl by aminophenyl fluorescein based assay	ic50	0.0060	uM
4-(7-fluoro-1H-indol-3-yl)butan-1-amine	738129: Inhibition of human recombinant MPO-mediated taurine chlorination after 5 mins by microplate assay	ic50	0.0060	uM
7-[(2,6-dichlorophenyl)methoxy]-2H-triazolo[4,5-b]pyridin-5-amine	1533019: Inhibition of human PMN leukocytes MPO peroxidation activity using H2O2 as substrate preincubated for 10 mins followed by H2O2 addition and measured for 15 mins by amplex red reagent based assay	ic50	0.0067	uM
7-[(2-fluorophenyl)methylsulfanyl]-2H-triazolo[4,5-b]pyridin-5-amine	1533018: Inhibition of human PMN leukocytes MPO chlorination activity using H2O2 as substrate preincubated for 10 mins followed by H2O2 addition and measured for 15 mins in presence of NaCl by aminophenyl fluorescein based assay	ic50	0.0068	uM
7-[(17S)-18-phenyl-16-oxa-2,8,9-triazapentacyclo[16.2.2.11,17.16,9.111,15]pentacosa-6(25),7,11(24),12,14-pentaen-5-yl]-2H-triazolo[4,5-b]pyridin-5-amine	1753665: Inhibition of MPO (unknown origin) chlorination activity incubated for 10 mins followed by NaCl addition by aminophenyl fluorescein assay	ic50	0.0070	uM
4-(5-fluoro-1H-indol-3-yl)butan-1-amine	1446226: Inhibition of recombinant MPO (unknown origin) assessed as reduction in taurine chloramine production preincubated with enzyme and taurine followed by H2O2 addition measured after 5 mins	ic50	0.0080	uM
7-(17-oxa-3,4,10-triazatetracyclo[17.3.1.13,6.112,16]pentacosa-1(23),4,6(25),12(24),13,15,19,21-octaen-7-yl)-2H-triazolo[4,5-b]pyridin-5-amine	1753665: Inhibition of MPO (unknown origin) chlorination activity incubated for 10 mins followed by NaCl addition by aminophenyl fluorescein assay	ic50	0.0080	uM
7-[[5-(difluoromethyl)-2-phenyltriazol-4-yl]methylsulfanyl]-2H-triazolo[4,5-b]pyridin-5-amine	1533019: Inhibition of human PMN leukocytes MPO peroxidation activity using H2O2 as substrate preincubated for 10 mins followed by H2O2 addition and measured for 15 mins by amplex red reagent based assay	ic50	0.0085	uM
3-[[(2R)-oxolan-2-yl]methyl]-2-sulfanylidene-7H-purin-6-one	1416577: Inhibition of human MPO assessed as reduction in enzyme-mediated chlorination by measuring reduction in HOCl formation preincubated for 10 mins followed by H2O2/NaCl addition and measured at 30 secs time interval for 5 mins by APF dye based fluorescence assay	ic50	0.0090	uM
7-[1-phenyl-3-[(1-phenyl-2-oxabicyclo[2.2.2]octan-4-yl)amino]propyl]-2H-triazolo[4,5-b]pyridin-5-amine	1698296: Inhibition of recombinant human MPO incubated for 10 mins in presence of 120 mM NaCl by aminophenyl fluorescein based assay	ic50	0.0093	uM
2-[3-(5-fluoro-1H-indol-3-yl)propylamino]ethanol	738129: Inhibition of human recombinant MPO-mediated taurine chlorination after 5 mins by microplate assay	ic50	0.0100	uM
2-[2-(5-fluoro-1H-indol-3-yl)ethylamino]ethanol	738129: Inhibition of human recombinant MPO-mediated taurine chlorination after 5 mins by microplate assay	ic50	0.0100	uM
N-[3-(5-fluoro-1H-indol-3-yl)propyl]hydroxylamine	738129: Inhibition of human recombinant MPO-mediated taurine chlorination after 5 mins by microplate assay	ic50	0.0110	uM
7-[[5-(difluoromethyl)-2-phenyltriazol-4-yl]methoxy]-2H-triazolo[4,5-b]pyridin-5-amine	1533019: Inhibition of human PMN leukocytes MPO peroxidation activity using H2O2 as substrate preincubated for 10 mins followed by H2O2 addition and measured for 15 mins by amplex red reagent based assay	ic50	0.0120	uM
1-[[4-chloro-2-[(1R)-1-(methylamino)ethyl]phenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one	1875005: Inhibition of MPO (unknown origin) measured after 15 mins in presence of H2O2 by chemiluminescence assay	ic50	0.0127	uM
N-benzyl-3-(5-fluoro-1H-indol-3-yl)propan-1-amine	1331722: Inhibition of MPO chlorination activity (unknown origin) assessed as taurine chloramine formation after 5 mins in presence of H2O2/Cl- by HTS method	ic50	0.0130	uM
7-(18-oxa-3,4,10-triazatetracyclo[17.3.1.13,6.113,17]pentacosa-1(23),4,6(25),13(24),14,16,19,21-octaen-7-yl)-2H-triazolo[4,5-b]pyridin-5-amine	1753665: Inhibition of MPO (unknown origin) chlorination activity incubated for 10 mins followed by NaCl addition by aminophenyl fluorescein assay	ic50	0.0140	uM
N-ethyl-N-[2-(5-fluoro-1H-indol-3-yl)ethyl]methanesulfonamide	738129: Inhibition of human recombinant MPO-mediated taurine chlorination after 5 mins by microplate assay	ic50	0.0140	uM
1-[[2-(aminomethyl)-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one	1875005: Inhibition of MPO (unknown origin) measured after 15 mins in presence of H2O2 by chemiluminescence assay	ic50	0.0150	uM
7-[(1R)-1-phenyl-3-[[(1R,3R)-3-phenylcyclopentyl]amino]propyl]-2H-triazolo[4,5-b]pyridin-5-amine	1698296: Inhibition of recombinant human MPO incubated for 10 mins in presence of 120 mM NaCl by aminophenyl fluorescein based assay	ic50	0.0150	uM
1-[[2-(azetidin-1-ylmethyl)phenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one	1875005: Inhibition of MPO (unknown origin) measured after 15 mins in presence of H2O2 by chemiluminescence assay	ic50	0.0151	uM
1-[[4-chloro-2-(methylaminomethyl)phenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one	1875005: Inhibition of MPO (unknown origin) measured after 15 mins in presence of H2O2 by chemiluminescence assay	ic50	0.0159	uM
7-[(3-chlorophenyl)methyl]-2H-triazolo[4,5-b]pyridin-5-amine	1698277: Inhibition of recombinant human MPO incubated for 10 mins in presence of 240 mM NaCl and 10 uM H2O2 by aminophenyl fluorescein based assay	ic50	0.0160	uM
methyl 3-[(5-amino-2H-triazolo[4,5-b]pyridin-7-yl)methyl]benzoate	1698278: Inhibition of recombinant human MPO incubated for 10 mins by amplex red dye based assay	ic50	0.0170	uM
3-[(5-amino-2H-triazolo[4,5-b]pyridin-7-yl)methyl]benzonitrile	1698277: Inhibition of recombinant human MPO incubated for 10 mins in presence of 240 mM NaCl and 10 uM H2O2 by aminophenyl fluorescein based assay	ic50	0.0170	uM
7-(18-oxa-3,4,10-triazatetracyclo[18.3.1.13,6.113,17]hexacosa-1(24),4,6(26),13(25),14,16,20,22-octaen-7-yl)-2H-triazolo[4,5-b]pyridin-5-amine	1753665: Inhibition of MPO (unknown origin) chlorination activity incubated for 10 mins followed by NaCl addition by aminophenyl fluorescein assay	ic50	0.0170	uM
N-[3-(5-fluoro-1H-indol-3-yl)propyl]butan-1-amine	547368: Inhibition of recombinant MPO mediated LDL oxidation using MPO/Cl-/H2O2 system	ic50	0.0170	uM
4-(5-fluoro-1H-indol-3-yl)butanamide	1446226: Inhibition of recombinant MPO (unknown origin) assessed as reduction in taurine chloramine production preincubated with enzyme and taurine followed by H2O2 addition measured after 5 mins	ic50	0.0180	uM

CTD chemical–gene interactions

201 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Hydrogen Peroxide	increases response to substance, affects activity, increases activity, increases chemical synthesis, increases degradation (+10 more)	13
Tetradecanoylphorbol Acetate	increases secretion, increases expression, increases activity, affects cotreatment, increases reaction (+2 more)	7
hydroquinone	affects cotreatment, increases metabolic processing, increases hydroxylation, affects reaction, increases cleavage (+4 more)	5
Benzene	increases metabolic processing, affects response to substance, increases response to substance	5
Hypochlorous Acid	increases chemical synthesis, increases metabolic processing, increases oxidation, increases abundance, increases reaction (+4 more)	5
Tretinoin	affects cotreatment, decreases expression, increases reaction, decreases reaction	5
Glutathione	increases glutathionylation, increases oxidation, increases activity, affects cotreatment, increases reaction (+3 more)	4
4-aminobenzhydrazide	decreases reaction, increases chemical synthesis, increases oxidation, decreases activity, affects response to substance	3
Benzo(a)pyrene	increases methylation, increases mutagenesis, affects response to substance	3
N-Formylmethionine Leucyl-Phenylalanine	decreases reaction, increases secretion, increases activity, increases reaction	3
Sodium Azide	increases activity, increases reaction, affects cotreatment, increases oxidation, increases chemical synthesis (+1 more)	3
chlorodimedone	increases metabolic processing, increases reaction, affects binding, decreases reaction, increases abundance	2
5,5-dimethyl-1-pyrroline-1-oxide	affects cotreatment, increases glutathionylation, increases reaction, increases activity, increases oxidation (+2 more)	2
epigallocatechin gallate	increases metabolic processing, affects cotreatment, decreases reaction, increases expression, increases chemical synthesis	2
Irinotecan	affects cotreatment, increases activity, decreases expression, increases reaction	2
Wortmannin	decreases reaction, increases chemical synthesis, increases phosphorylation, increases secretion, affects cotreatment	2
Arsenic Trioxide	affects cotreatment, decreases expression, decreases reaction	2
Carvedilol	decreases reaction, increases secretion	2
Acetylcysteine	increases reaction, increases chemical synthesis, affects binding, affects cotreatment, increases oxidation	2
Aminoglutethimide	affects cotreatment, increases oxidation, increases metabolic processing, increases expression	2
Chlorine	affects binding, increases oxidation, increases reaction, decreases activity	2
Cisplatin	decreases expression, affects response to substance	2
Indomethacin	increases activity, increases oxidation, increases response to substance, decreases reaction, increases chemical synthesis	2
Lipopolysaccharides	increases expression, decreases reaction	2
Penicillamine	increases oxidation, increases reaction, increases chemical synthesis, decreases secretion	2
Tobacco Smoke Pollution	increases response to substance, decreases expression	2
Valproic Acid	increases methylation, affects expression	2
aristolochic acid I	increases expression	1
4-methoxybenzohydrazide	decreases reaction, increases oxidation, decreases activity	1
GSK484	affects cotreatment, decreases reaction, increases activity	1

ChEMBL screening assays

178 unique, capped per target: 165 binding, 9 functional, 4 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1027367	Binding	Inhibition of MPO activity in TNF-alpha-stimulated human HL60 cells measured enzyme activity per 10'6 cells by spectrophotometrically	Chemical components and its antioxidant properties in vitro: an edible marine brown alga, Ecklonia cava. — *Bioorg Med Chem*
CHEMBL3636512	ADMET	Drug metabolism assessed as formation of human MPO-mediated PTU-disulfide at 10 uM after 60 mins by LC-MS/MS analysis in presence of H2O2/Cl-	Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular Diseases. — *J Med Chem*
CHEMBL750554	Functional	In vivo agonist efficacy as the maximal lysosomal myeloperoxidase (MPO) release in PMNL assay	Improvements in the minimum binding sequence of C5a: examination of His-67. — *J Med Chem*

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B8KQ	Abcam HCT 116 MPO KO	Cancer cell line	Male
CVCL_B9MY	Abcam A-549 MPO KO	Cancer cell line	Male

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

showing 60 of 299 trials:

NCT	Phase	Status	Title
NCT04520308	Phase 4	UNKNOWN	An Open-label, Single-arm Longitudinal Study With Dupilumab for Patients With Atopic Dermatitis
NCT00009191	Phase 4	COMPLETED	The Depression in Alzheimer’s Disease Study (DIADS)
NCT00009217	Phase 4	COMPLETED	Treatment of Behavioral Symptoms in Alzheimer’s Disease
NCT00018278	Phase 4	COMPLETED	Electrophysiologic Measures of Treatment Response in Alzheimer Disease
NCT00035204	Phase 4	COMPLETED	A Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Galantamine and Donepezil in Patients With Alzheimer’s Disease
NCT00042172	Phase 4	COMPLETED	Treatment for Early Memory Loss
NCT00046358	Phase 4	COMPLETED	The Effect of Short-Term Statins and NSAIDs on Levels of Beta-Amyloid, a Protein Associated With Alzheimer’s Disease
NCT00104442	Phase 4	COMPLETED	Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer’s Disease
NCT00120874	Phase 4	COMPLETED	Memantine and Comprehensive, Individualized Management of Alzheimer’s Disease and Caregiver Training
NCT00142324	Phase 4	UNKNOWN	CALM-AD
NCT00165724	Phase 4	COMPLETED	Alzheimer’s Disease Long-term Follow-up Study (ALF Study)
NCT00165750	Phase 4	TERMINATED	Correlation Between Regional Brain Volume and Response to Donepezil Treatment in AD Patients
NCT00202124	Phase 4	COMPLETED	Double Blind Study of Trp01 in Patients With Alzheimer’s Disease
NCT00208819	Phase 4	COMPLETED	A Comparison of Two Standard Therapies in the Management of Dementia With Agitation
NCT00216515	Phase 4	COMPLETED	The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type
NCT00230568	Phase 4	COMPLETED	EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer’s Disease (AD)
NCT00234637	Phase 4	COMPLETED	Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer’s Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment
NCT00245206	Phase 4	COMPLETED	Side Effects of Newer Antipsychotics in Older Adults
NCT00254033	Phase 4	COMPLETED	Apathy Associated With Alzheimer’s Disease
NCT00260624	Phase 4	COMPLETED	Escitalopram Treatment of Patients With Agitated Dementia
NCT00303277	Phase 4	COMPLETED	Do HMG CoA Reductase Inhibitors Affect Abeta Levels?
NCT00305903	Phase 4	COMPLETED	Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer’s Disease
NCT00306124	Phase 4	UNKNOWN	Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dementia/Mild Cognitive Impairment
NCT00334906	Phase 4	COMPLETED	Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer’s Disease)
NCT00369603	Phase 4	TERMINATED	Functional Brain Imaging of Medication Treatment Response in Mild Alzheimer’s Disease Patients
NCT00375557	Phase 4	WITHDRAWN	Safety and Efficacy of Divalproex and Quetiapine in Elderly Alzheimer’s Dementia Patients
NCT00381381	Phase 4	COMPLETED	The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer’s Disease
NCT00385684	Phase 4	COMPLETED	Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)
NCT00401167	Phase 4	COMPLETED	Memantine for Agitation and Aggression in Severe Alzheimer’s Disease
NCT00403520	Phase 4	COMPLETED	Hippocampus Study: Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers
NCT00417482	Phase 4	COMPLETED	Antipsychotic Discontinuation in Alzheimer’s Disease
NCT00443014	Phase 4	COMPLETED	The Dementia Study in Northern Norway
NCT00469456	Phase 4	COMPLETED	Effect of Memantine on Functional Communication in Patients With Alzheimer’s Disease
NCT00476008	Phase 4	COMPLETED	Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer’s Disease
NCT00477659	Phase 4	COMPLETED	Neural Correlates In Mild Alzheimer’s Disease
NCT00480870	Phase 4	COMPLETED	The Effect of Anticholinesterase Drugs on Sleep in Alzheimer’s Disease Patients
NCT00495820	Phase 4	COMPLETED	Methylphenidate for Apathy in Alzheimer’s Dementia: A Controlled Study
NCT00523666	Phase 4	UNKNOWN	Diffusion Tensor Weighted MRI in Alzheimer’s Disease Modifying Treatment Effects of Galantamine (Reminyl®)
NCT00549601	Phase 4	COMPLETED	Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer’s Disease
NCT00551161	Phase 4	COMPLETED	Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer’s Disease
NCT00561392	Phase 4	COMPLETED	Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer’s Disease
NCT00622713	Phase 4	COMPLETED	A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer’s Disease (EXTRA)
NCT00626210	Phase 4	TERMINATED	Modafinil Treatment for Sleep/Wake Disturbances in Older Adults
NCT00626613	Phase 4	UNKNOWN	The Relationship Between Risperdal Treatment and Quality of Life in Patients With Alzheimer’s Disease and Behavioural and Psychological Symptoms of Dementia (BPSD)
NCT00649220	Phase 4	TERMINATED	Memantine and Antipsychotics Use
NCT00706186	Phase 4	TERMINATED	Safety and Feasibility of Sodium Oxybate in Mild Alzheimer’s Disease Patients
NCT00711204	Phase 4	WITHDRAWN	Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer’s Disease
NCT00731224	Phase 4	COMPLETED	Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer’s Disease.
NCT00792662	Phase 4	WITHDRAWN	Improving Function, Quality of Life, Glycemia in Diabetics With Dementia
NCT00800709	Phase 4	COMPLETED	Memantine and Changes of Biological Markers and Brain PET Imaging in Alzheimer’s Disease
NCT00862940	Phase 4	COMPLETED	A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer’s Disease
NCT00933608	Phase 4	COMPLETED	Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer’s Disease
NCT00948766	Phase 4	COMPLETED	Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer’s Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44
NCT00950430	Phase 4	ENROLLING_BY_INVITATION	Imaging of Brain Amyloid Plaques in the Aging Population
NCT00980785	Phase 4	COMPLETED	Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer’s
NCT01025466	Phase 4	COMPLETED	Exelon Patch and Combination With Memantine Comparative Trial
NCT01047579	Phase 4	COMPLETED	A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer’s Disease
NCT01054976	Phase 4	COMPLETED	The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer’s Disease
NCT01119638	Phase 4	COMPLETED	Escitalopram Treatment for BPSD in Alzheimer’s Disease in Comparison to Risperidone
NCT01122329	Phase 4	COMPLETED	A Positron Emission Tomography (PET) Study Evaluating Brain Metabolism of a Medical Food in Alzheimer’s Disease

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for MPO across ~30M SureChEMBL compounds — explore on Sugi Predict.